A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types.

ABSTRACT:

Purpose

An integrated population pharmacokinetic (popPK) model was developed to describe the pharmacokinetics (PK) of tyrosine kinase inhibitor cabozantinib in healthy volunteers (HVs) and patients with various cancer types and to identify any differences in cabozantinib PK across these populations.

Methods

Plasma concentration data used to develop the popPK model were obtained from nine clinical trials (8072 concentrations from 1534 HVs or patients) of cabozantinib in HVs and patients with renal cell carcinoma (RCC), medullary thyroid carcinoma (MTC), glioblastoma multiforme, castration-resistant prostate cancer, or other advanced malignancies.

Results

PK data across studies were adequately characterized by a two-compartment disposition model with dual first- and zer

SUBMITTER: Lacy S 

PROVIDER: S-EPMC5973963 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature